Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Natural Bioactive Compounds Acting against Oxidative Stress in Chronic, Degenerative, and Infectious Diseases.

Mattioli R, Mosca L, Sánchez-Lamar A, Tempera I, Hausmann R.

Oxid Med Cell Longev. 2018 Dec 3;2018:3894381. doi: 10.1155/2018/3894381. eCollection 2018. No abstract available.

2.

Poly(ADP-ribosylated) proteins in β-amyloid peptide-stimulated microglial cells.

Correani V, Martire S, Mignogna G, Caruso LB, Tempera I, Giorgi A, Grieco M, Mosca L, Schininà ME, Maras B, d'Erme M.

Biochem Pharmacol. 2018 Nov 9. pii: S0006-2952(18)30453-2. doi: 10.1016/j.bcp.2018.10.026. [Epub ahead of print]

PMID:
30414941
3.

Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1.

Hulse M, Caruso LB, Madzo J, Tan Y, Johnson S, Tempera I.

PLoS Pathog. 2018 Nov 5;14(11):e1007394. doi: 10.1371/journal.ppat.1007394. eCollection 2018 Nov.

4.

PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type.

Lupey-Green LN, Caruso LB, Madzo J, Martin KA, Tan Y, Hulse M, Tempera I.

J Virol. 2018 Aug 29;92(18). pii: e00755-18. doi: 10.1128/JVI.00755-18. Print 2018 Sep 15.

5.

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage.

Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I.

Oncotarget. 2018 Jan 24;9(12):10585-10605. doi: 10.18632/oncotarget.24291. eCollection 2018 Feb 13.

6.

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T.

Blood Adv. 2017 Aug 9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. eCollection 2017 Aug 22.

7.

Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.

Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N, Gamero AM, Soboloff J, Tempera I, Zaidi MR.

Cancer Res. 2018 Jan 15;78(2):436-450. doi: 10.1158/0008-5472.CAN-17-1615. Epub 2017 Nov 17.

8.

IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T.

Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20.

9.

Poly(ADP-ribosylated) proteins in mononuclear cells from patients with type 2 diabetes identified by proteomic studies.

Giorgi A, Tempera I, Napoletani G, Drovandi D, Potestà C, Martire S, Mandosi E, Filardi T, Eugenia Schininà M, Morano S, d'Erme M, Maras B.

Acta Diabetol. 2017 Sep;54(9):833-842. doi: 10.1007/s00592-017-1013-y. Epub 2017 Jun 12.

PMID:
28608282
10.

PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.

Lupey-Green LN, Moquin SA, Martin KA, McDevitt SM, Hulse M, Caruso LB, Pomerantz RT, Miranda JL, Tempera I.

Virology. 2017 Jul;507:220-230. doi: 10.1016/j.virol.2017.04.006. Epub 2017 Apr 26.

11.

HIV-1 Vpr disrupts mitochondria axonal transport and accelerates neuronal aging.

Wang Y, Santerre M, Tempera I, Martin K, Mukerjee R, Sawaya BE.

Neuropharmacology. 2017 May 1;117:364-375. doi: 10.1016/j.neuropharm.2017.02.008. Epub 2017 Feb 14.

12.

Novel STIM1-dependent control of Ca2+ clearance regulates NFAT activity during T-cell activation.

Samakai E, Hooper R, Martin KA, Shmurak M, Zhang Y, Kappes DJ, Tempera I, Soboloff J.

FASEB J. 2016 Nov;30(11):3878-3886. Epub 2016 Aug 15.

13.

Alterations in nuclear structure promote lupus autoimmunity in a mouse model.

Singh N, Johnstone DB, Martin KA, Tempera I, Kaplan MJ, Denny MF.

Dis Model Mech. 2016 Aug 1;9(8):885-97. doi: 10.1242/dmm.024851. Epub 2016 Jun 9.

14.

Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.

Martin KA, Lupey LN, Tempera I.

J Virol. 2016 Sep 12;90(19):8520-30. doi: 10.1128/JVI.01180-16. Print 2016 Oct 1.

15.

Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.

Tempera I, De Leo A, Kossenkov AV, Cesaroni M, Song H, Dawany N, Showe L, Lu F, Wikramasinghe P, Lieberman PM.

J Virol. 2015 Oct 14;90(1):345-55. doi: 10.1128/JVI.02318-15. Print 2016 Jan 1.

16.

Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2.

Martin KA, Cesaroni M, Denny MF, Lupey LN, Tempera I.

Mol Cell Biol. 2015 Dec;35(23):3934-44. doi: 10.1128/MCB.00635-15. Epub 2015 Sep 14.

17.

Epigenetic regulation of EBV persistence and oncogenesis.

Tempera I, Lieberman PM.

Semin Cancer Biol. 2014 Jun;26:22-9. doi: 10.1016/j.semcancer.2014.01.003. Epub 2014 Jan 24. Review.

18.

EBNA1 binding and epigenetic regulation of gastrokine tumor suppressor genes in gastric carcinoma cells.

Lu F, Tempera I, Lee HT, Dewispelaere K, Lieberman PM.

Virol J. 2014 Jan 24;11:12. doi: 10.1186/1743-422X-11-12.

19.

Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site.

Chen HS, Martin KA, Lu F, Lupey LN, Mueller JM, Lieberman PM, Tempera I.

J Virol. 2014 Feb;88(3):1703-13. doi: 10.1128/JVI.02209-13. Epub 2013 Nov 20.

20.

CTCF binding site sequence differences are associated with unique regulatory and functional trends during embryonic stem cell differentiation.

Plasschaert RN, Vigneau S, Tempera I, Gupta R, Maksimoska J, Everett L, Davuluri R, Mamorstein R, Lieberman PM, Schultz D, Hannenhalli S, Bartolomei MS.

Nucleic Acids Res. 2014 Jan;42(2):774-89. doi: 10.1093/nar/gkt910. Epub 2013 Oct 10.

21.

PARP-1 modulates amyloid beta peptide-induced neuronal damage.

Martire S, Fuso A, Rotili D, Tempera I, Giordano C, De Zottis I, Muzi A, Vernole P, Graziani G, Lococo E, Faraldi M, Maras B, Scarpa S, Mosca L, d'Erme M.

PLoS One. 2013 Sep 24;8(9):e72169. doi: 10.1371/journal.pone.0072169. eCollection 2013.

22.

Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data.

Arvey A, Tempera I, Lieberman PM.

Viruses. 2013 Apr 2;5(4):1042-54. doi: 10.3390/v5041042. Review.

23.

An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions.

Arvey A, Tempera I, Tsai K, Chen HS, Tikhmyanova N, Klichinsky M, Leslie C, Lieberman PM.

Cell Host Microbe. 2012 Aug 16;12(2):233-45. doi: 10.1016/j.chom.2012.06.008.

24.

EBV latency types adopt alternative chromatin conformations.

Tempera I, Klichinsky M, Lieberman PM.

PLoS Pathog. 2011 Jul;7(7):e1002180. doi: 10.1371/journal.ppat.1002180. Epub 2011 Jul 28.

25.

Biological effects of MC2050, a quinazoline-based PARP-1 inhibitor, in human neuroblastoma and EBV-positive Burkitt's lymphoma cells.

Mosca L, Rotili D, Tempera I, Masci A, Fontana M, Chiaraluce R, Mastromarino P, d'Erme M, Mai A.

ChemMedChem. 2011 Apr 4;6(4):606-11. doi: 10.1002/cmdc.201000536. Epub 2011 Mar 1. No abstract available.

PMID:
21365766
26.

CTCF prevents the epigenetic drift of EBV latency promoter Qp.

Tempera I, Wiedmer A, Dheekollu J, Lieberman PM.

PLoS Pathog. 2010 Aug 12;6(8):e1001048. doi: 10.1371/journal.ppat.1001048.

27.

Regulation of Epstein-Barr virus OriP replication by poly(ADP-ribose) polymerase 1.

Tempera I, Deng Z, Atanasiu C, Chen CJ, D'Erme M, Lieberman PM.

J Virol. 2010 May;84(10):4988-97. doi: 10.1128/JVI.02333-09. Epub 2010 Mar 10.

28.

Chromatin organization of gammaherpesvirus latent genomes.

Tempera I, Lieberman PM.

Biochim Biophys Acta. 2010 Mar-Apr;1799(3-4):236-45. doi: 10.1016/j.bbagrm.2009.10.004. Epub 2009 Oct 22. Review.

29.

GD3 nuclear localization after apoptosis induction in HUT-78 cells.

Tempera I, Buchetti B, Lococo E, Gradini R, Mastronardi A, Mascellino MT, Sale P, Mosca L, d'Erme M, Lenti L.

Biochem Biophys Res Commun. 2008 Apr 11;368(3):495-500. doi: 10.1016/j.bbrc.2007.12.196. Epub 2008 Feb 7.

PMID:
18261989
30.

Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression.

Mattiussi S, Tempera I, Matusali G, Mearini G, Lenti L, Fratarcangeli S, Mosca L, D'Erme M, Mattia E.

Infect Agent Cancer. 2007 Oct 11;2:18.

31.

Characterization of catechol-thioether-induced apoptosis in human SH-SY5Y neuroblastoma cells.

Mosca L, Tempera I, Lendaro E, Di Francesco L, d'Erme M.

J Neurosci Res. 2008 Mar;86(4):954-60.

PMID:
17929313
32.

Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients.

Tempera I, Cipriani R, Campagna G, Mancini P, Gatti A, Guidobaldi L, Pantellini F, Mandosi E, Sensi M, Quesada P, Mario UD, D'Erme M, Morano S.

J Cell Physiol. 2005 Dec;205(3):387-92.

PMID:
15895395

Supplemental Content

Loading ...
Support Center